Rahway said this week it hopes to have fully-scaled stock available for the Spring 2025 RSV infections "season". And we should note that both GSK and Pfizer now offer approved vaccines for RSV -- so the uptake on the therapy may "only" reach around $700 million a year, at peak sales -- in a few years' time, for Merck. Still, it is very good news -- per Fierce Biotech's reporting:
. . .Three months after revealing that its respiratory syncytial virus (RSV) preventive antibody clesrovimab had passed muster in a phase 2b/3 trial, Merck is putting numbers to the claim.
Clesrovimab, also known as MK-1654, scored on multiple trial endpoints, demonstrating its ability to protect infants against the virus in their first RSV season.
With the results, which were presented Thursday in Los Angeles during IDWeek 2024, Merck said it hopes to bring clesrovimab to the market for the 2025-26 RSV season. . . .
Clesrovimab achieved its primary objective by reducing the incidence of RSV-associated medically attended lower respiratory infections requiring at least one indicator of lower respiratory infection by 60% versus placebo through the first five months after dosing, the company said.
The drug also reduced RSV-related hospitalizations (secondary endpoint) and RSV-related lower respiratory infection hospitalizations (tertiary endpoint) by 84% and 91%, respectively, versus placebo through five months. . . .
Now you know -- and onward, to a Buff win tomorrow afternoon, in the Arizona desert heat. Grin. . . .
नमस्ते
No comments:
Post a Comment